Table 1 Representative targets within the lipid metabolism pathway for anti-cancer drug development

SCAP

–

GBM

Xenografts

–

[55]

SREBPs

Fatostatin, betulin, PF-429242, xanthohumol

GBM, prostate, liver, skin, melanoma, colorectal, bile duct, pancreatic, and breast cancer

Xenografts

–

[28, 125,126,127,128,129,130,131,132,133,134,135,136,137,138]

ACCs

TOFA, soraphen A, ND-646

Lung, ovarian cancer, head and neck squamous cell carcinoma

Xenografts

–

[179,180,181,182,183,184,185]

ACLY

SB-204990, bempedoic acid, BMS303141

Lung, prostate, and ovarian cancer

Xenografts

–

[152, 162, 165]

FASN

Cerulenin

Ovarian cancer, breast cancer

Xenografts

–

[179, 194,195,196]

C75

Breast, GBM, renal, and mesothelioma cancer

Xenografts

–

[34, 179, 188, 197,198,199,200,201,202,203]

TVB-2640

Solid malignant tumors

–

Phase I

Clinicaltrials.gov (NCT02223247), [191]

TVB-3166

Lung, ovary, and pancreatic cancer

Xenografts

–

[264]

C93

Ovarian and lung cancer

Xenografts

–

[265, 266]

C247

Breast cancer

–

[267]

Orlistat

Prostate cancer and melanoma

Xenografts

–

[192, 193]

Triclosan

Breast cancer

Xenografts

–

[268, 269]

LDLR

–

GBM

–

–

[27, 219]

SCD1

BZ36, A939572, MF-438

Prostate, renal cancer

Xenografts

–

[124, 212,213,214,215, 270]

LXR

GW3965, LXR-623

GBM

Xenografts

–

[27, 238, 239]

SR9243

Prostate cancer

Xenografts

[242]

SOAT1 (or ACAT1)

K604, ATR-101, avasimibe

GBM, prostate and pancreatic cancer

Xenografts

–

[28, 230,231,232]

CPT1

Etomoxir, perhexiline

Leukemia, prostate and breast cancer

Xenografts, transgenic mice

–

[248,249,250, 271, 272]

CD36

Anti-CD36 antibodies

Oral cancer

Xenografts

–

[24,25,26]